Author: Ken Dropiewski

Tryton medical receives FDA approval for Tryton side branch stent to treat significant coronary bifurcation lesions

PCRonline/News/Industry Press Releases Tryton stent is the first dedicated bifurcation device to receive regulatory approval in the U.S. Cordis to be exclusive U.S. distributor of the Tryton stent. DURHAM, N.C. – Tryton Medical, Inc., the leading developer of stents designed to treat coronary bifurcation lesions, today announced the U.S. Food […]

Keystone Heart Applauds FDA Advisory Panel for Recognition of The Need for Cerebral Protection Following TAVR

CAESAREA, Israel and TAMPA, Fla., Feb. 27, 2017 /PRNewswire/ — Keystone Heart Ltd., an emerging medical device company focused on developing cerebral embolic protection devices for patients undergoing cardiac procedures, applauds the members of the FDA’s Circulatory System Devices Panel that convened this past week for their acknowledgement of the […]

CEO and Co-founder of Renova Therapeutics to present at Novel Cardiovascular Therapeutics Summit

SAN DIEGO, Feb. 27, 2017 /PRNewswire-USNewswire/ — Renova™ Therapeutics, a biotechnology company developing gene therapy treatments for congestive heart failure and type 2 diabetes, announced that the company’s CEO and Co-founder, Jack W. Reich, Ph.D., will be speaking at the Novel Cardiovascular Therapeutics Summit in San Francisco on February 28, […]